Intravitreal Triamcinolone Acetonide as Treatment of Neovascular Glaucoma
Heyer C., Kreissig I., Budde W. M., Degenring R. F.
Department of Ophthalmology and Eye Hospital, Faculty for Clinical Medicine Mannheim, Ruprecht-Karls-University, Heidelberg
Purpose: To evaluate safety and efficacy of intravitreal triamcinolone for treatment of neovascular glaucoma.
Method: The clinical interventional comparative case series study included 18 patients (18 eyes) with neovascular glaucoma due to proliferative diabetic retinopathy (n=11) or ischemic central retinal vein occlusion (n=7). All patients received an intravitreal injection of 25 mg of triamcinolone acetonide. The total study population was divided into a study group consisting of 5 eyes with an intravitreal injection and into a control group consisting of 13 eyes in which the intravitreal triamcinolone injection was combined with a peripheral circumferential transscleral retinal cryocoagulation. Mean follow-up was 5.4 ± 4.2 months. Main outcome measures were visual acuity, intraocular pressure, and degree of iris neovascularization.
Results: In the total study population, intraocular pressure was significantly (p=0.003) reduced from 35.9 ± 12.7 mm Hg preoperatively to 20.6 ± 11.0 mm Hg postoperatively. Degree of rubeosis iridis decreased significantly (p=0.02) from 2.7 ± 1.2 relative units to 1.3 ± 1.2 relative units. Group and control group did not vary significantly, best postoperative visual acuity (p=0.78), reduction in intraocular pressure (p=0.85) and decrease of the retinal neovascularisation (p=0,85).
Zurück | Back